1[1]Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999 - 2000[J]. JAMA, 2002,288:1723 - 1727
2[2]Ford ES,Giles WH, Dietz WH. Prevalence of the metabolic syndrome, among US adults: findings form the third National Health and Nutrition Examination Survey[J ]. JAMA, 2002,287: 356 - 359
3[3]Executive Summary of the Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ ) [J]. JAMA, 2001,285:2486 - 2497
4[4]Sakkinen PA,Wahl P, Cushman M, et al. Clustering of procoagulation. Inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome[J]. Am J Epidemiol, 2000,152: 897 - 907
5[5]Reaven GM. Banting Lecture 1988 Role of insulin resistance in human disease[ J ]. Diabetes, 1988,37:1595- 1607
6[6]Abate N,Garg A. Heterogeneity in adipose tissue metabolism:causes, implications and management of regional adiposity[J]. Prog Lipid Res, 1995,34: 53 - 70
7[7]Nieves DJ, Cnop M, Retzlaff B, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra- abdominal fat[J]. Diabetes,2003,52:172 - 179
8[8]Steppan CM, Lazar MA. Resistin and obesity - associated insulin resistance [ J ]. Trends Endocrinol Metab,2002,13:18023
9[9]Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and he risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS)[J]. Circulation, 2001,104: 39052 - 39056
10[10]Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduce atherosclerosis in apolipoprotein E - dificient mice[J]. Circulation, 2002,106: 2767 - 2770
